Literature DB >> 23103883

Concurrent deletion of BMP4 and OTX2 genes, two master genes in ophthalmogenesis.

Toshiki Takenouchi1, Sachiko Nishina, Rika Kosaki, Chiharu Torii, Ritsuko Furukawa, Takao Takahashi, Kenjiro Kosaki.   

Abstract

BMP4 and OTX2 are master genes in ophthalmogenesis. Mutations of BMP4 and OTX2 often lead to eye defects, including anophthalmia-microphthalmia. A significant degree of variable expressivity has been reported in heterozygous individuals with BMP4 or OTX2 mutation. Interestingly, both BMP4 and OTX2 reside on 14q22, being only 2.8 Mb apart. Previous studies reported that among three patients with 14q22 deletion involving BMP4 and OTX2, all had severe eye defects. The minimal degree of variable expressivity among these individuals who were doubly deleted for BMP4 and OTX2 could be attributed to the combinatorial relationship of the two genes observed in animal models. We herein report a patient with a concurrent deletion of BMP4 and OTX2 who exhibited bilateral microphthalmia, more specifically, anterior segment dysgenesis with microcornea. Evolutionarily conserved physical linkage of Bmp4 and Otx2 loci may suggest an advantage of the proximal alignment of the two genes. Another striking feature in the propositus was the progressive white matter loss observed by serial neuroimaging. A review of twelve previously reported patients with 14q22 microdeletion revealed decreased white matter volume in half of the patients. It remains to be elucidated whether the white matter lesion is age-dependent and progressive. In conclusion, anterior segment defects of the eyes, especially when accompanied by decreased white matter volume on neuroimaging, should raise the clinical suspicion of 14q22 microdeletion.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23103883     DOI: 10.1016/j.ejmg.2012.10.007

Source DB:  PubMed          Journal:  Eur J Med Genet        ISSN: 1769-7212            Impact factor:   2.708


  6 in total

Review 1.  Extracellular matrix in the trabecular meshwork: intraocular pressure regulation and dysregulation in glaucoma.

Authors:  Janice A Vranka; Mary J Kelley; Ted S Acott; Kate E Keller
Journal:  Exp Eye Res       Date:  2015-04       Impact factor: 3.467

Review 2.  Genetics of Combined Pituitary Hormone Deficiency: Roadmap into the Genome Era.

Authors:  Qing Fang; Akima S George; Michelle L Brinkmeier; Amanda H Mortensen; Peter Gergics; Leonard Y M Cheung; Alexandre Z Daly; Adnan Ajmal; María Ines Pérez Millán; A Bilge Ozel; Jacob O Kitzman; Ryan E Mills; Jun Z Li; Sally A Camper
Journal:  Endocr Rev       Date:  2016-11-09       Impact factor: 19.871

Review 3.  Genetics of anophthalmia and microphthalmia. Part 2: Syndromes associated with anophthalmia-microphthalmia.

Authors:  Anne Slavotinek
Journal:  Hum Genet       Date:  2018-10-30       Impact factor: 4.132

4.  Bone Morphogenetic Protein (BMP) signaling in development and human diseases.

Authors:  Richard N Wang; Jordan Green; Zhongliang Wang; Youlin Deng; Min Qiao; Michael Peabody; Qian Zhang; Jixing Ye; Zhengjian Yan; Sahitya Denduluri; Olumuyiwa Idowu; Melissa Li; Christine Shen; Alan Hu; Rex C Haydon; Richard Kang; James Mok; Michael J Lee; Hue L Luu; Lewis L Shi
Journal:  Genes Dis       Date:  2014-09

5.  Novel BMP4 Truncations Resulted in Opposite Ocular Anomalies: Pathologic Myopia Rather Than Microphthalmia.

Authors:  Yi Jiang; Jiamin Ouyang; Xueqing Li; Yingwei Wang; Lin Zhou; Shiqiang Li; Xiaoyun Jia; Xueshan Xiao; Wenmin Sun; Panfeng Wang; Qingjiong Zhang
Journal:  Front Cell Dev Biol       Date:  2021-12-01

6.  Anophthalmia, hearing loss, abnormal pituitary development and response to growth hormone therapy in three children with microdeletions of 14q22q23.

Authors:  Sophie Brisset; Zuzana Slamova; Petra Dusatkova; Audrey Briand-Suleau; Karen Milcent; Corinne Metay; Martina Simandlova; Zdenek Sumnik; Lucie Tosca; Michel Goossens; Philippe Labrune; Elsa Zemankova; Jan Lebl; Gerard Tachdjian; Zdenek Sedlacek
Journal:  Mol Cytogenet       Date:  2014-02-28       Impact factor: 2.009

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.